EirGenix Makes Progress With Trastuzumab Biosimilar

Company Plans To Submit Filings To Both FDA and EMA

 
• By Akriti Seth
clinical trials
EirGenix sees positive Phase III results for its Herceptin biosimilar • Source: Shutterstock

More from Biosimilars

More from Products